- Quality, Affordable Healthcare with High Barriers-to-Entry: Sergeant's primary OTC channel flea and tick products contain the same active ingredients as the leading veterinary channel national brands, but offer consumers and retailers a compelling value proposition. In addition to regulatory hurdles (e.g., Environmental Protection Agency, Food and Drug Administration compliance), intellectual property portfolios, active-ingredient sourcing and channel access create barriers-to-entry.
- Immediate Access to Adjacent Category: The transaction is aligned with the Company's strategic growth objective to expand into adjacent categories where Perrigo can drive enhanced product offerings and value for its retail customers.
- Entry into Sizeable and Growing Self-pay Market: Pet Care is an $8 billion industry that has shown consistent growth through economic cycles. Consumers are treating their pets like members of the family and are spending a higher proportion of discretionary income on pet care and well-being.
- Revenue Synergies: Sergeant's acquisition allows Perrigo to add products to its current offerings and leverage established distribution infrastructure and customer relationships.
- Compelling Value Consistent with Stated Acquisition Criteria: The transaction is expected to be immediately accretive to adjusted earnings per share. The transaction is expected to be approximately $0.12 accretive to GAAP earnings per share and, excluding $0.08 of estimated deal-related expenses and intangible amortization, $0.20 accretive to adjusted earnings per share in the first full fiscal year post-closing. Perrigo's stated goal of Return on Invested Capital accretion is expected to be achieved in fiscal 2014.
Perrigo Company To Acquire Assets Of Sergeant's Pet Care Products, Inc., For $285 Million
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts